COMPANY PROFILE

Waypoint Bio

Explore full profile

Pioneering high-throughput in vivo testing to develop novel cell therapies for solid tumors and autoimmune diseases

New York City, United StatesFounded 2021Biotech & Life Sciences

Valuation $100–250M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Waypoint Bio

Waypoint Bio is at the forefront of developing innovative cell therapies aimed at treating solid tumors and autoimmune diseases. Utilizing a proprietary spatial multi-omics platform, the company addresses critical challenges in understanding how cell therapies interact within the three-dimensional tumor microenvironment. This technology enables the measurement of both cell-to-cell and cell-to-environment interactions, providing a comprehensive view of cellular behavior. Waypoint Bio serves clients in the biotechnology and pharmaceutical sectors, focusing on high-throughput in vivo testing to ensure both speed and quality in therapy development. The business model revolves around leveraging its advanced spatial biology technology to offer unique insights and solutions, thereby generating revenue through partnerships and service contracts with industry players. The company's market includes researchers and developers looking for cutting-edge tools to enhance the efficacy and safety of cell therapies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2021
Headquarters: New York City, United States
Employees: 19
Open positions: 2
Dealroom signal: 81.7/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Technology: Big Data
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	May 2026	$20M	$80M	Time BioVentures · General Catalyst · Hummingbird Ventures · Lux Capital	↗
SEED✓Equity / VC	Jun 2024	$15M	$58M	Boom Capital Ventures · Recode Health Ventures · Hummingbird Ventures · Fifty Years	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Waypoint Bio website traffic

Latest recorded traffic for Waypoint Bio is 4.6K monthly website visits, up 48.4% over the last three months. Waypoint Bio's team grew 0% over the past year.

Latest monthly visits4.6K 3-month web change+48.4% 1-year team growth0%

Monthly website visitsNov 2023–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Open positions

Openings linked to this company in Dealroom

Part-time Associate Scientist, In Vivo Cancer BiologyNew York, NY · Other · Jul 2, 2026 Scientist / Senior Scientist, Genetic EngineeringNew York, NY · Other · Jun 12, 2026

2 distinct openings shownExplore hiring signals →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
LBLeo Summit BiotechnologyCreating a characteristic research and development platform combining "engineering center + expert think tank + postdoctoral workstation" combining production, learning and research	China	Operational	—	$5.5M	$11M
AIAirBiometricsHelps to regain sovereignty over well-being	Castellón de la Plana, Spain	Operational
DIDeep Pharma IntelligenceThe leading UK-based market intelligence agency focused on the emerging markets in the Pharmaceutical, Biotech, and Healthcare industries	London, United Kingdom	Operational
YBYatiri BioYatiri Bio – Beyond Genes	San Diego, United States	Operational
SESeekGeneProvider of genetic data analysis solutions focused on the development and clinical transformation	Guangzhou, China	Operational
MIMelliCell, Inc.Develops therapeutics for diabetes and obesity using proprietary technologies that model weight gain in human fat cells in vitro	Newton, United States	Operational
DEDeepflareDeepflare is an AI company helping pharma firms accelerate cancer vaccine and immunotherapy development	Warsaw, Poland	Operational
DADigid - Digital Diagnostics AGDigid \| Digital Diagnostics AG	Mainz, Germany	Operational